







Hepatitis C therapy in 2011: is less more, is more less?
The year 2011 will be an extraordinary one. 
Twenty-two years after the discovery of hepati-
tis C virus (HCV) we finally have a therapy that 
acts directly on the virus. We have entered the 
era of therapy with direct-acting antiviral agents 
(DAAs). During therapy evolution, we have 
always searched for a term that would charac-
terize the current modality. We relinquished the 
“one size fits all”, then the “a la carte” therapy, 
in which dose customization is essential. We have 
recently started using response-guided therapy 
(RGT), in which the duration of therapy is de-
fined according to the moment of HCV non-de-
tection. And now, after the first protease inhibi-
tors (PIs) have been approved, will it be possible 
to define therapy through a new expression? I be-
lieve the discussion and therapeutic decisions will 
gravitate around the binomial safety-compliance, 
and then, less is more, or more is less, should be 
the best definition for this new era. 
The addition of PIs generates a higher rate of 
sustained viral response (SVR) in treatment-naïve 
patients, relapsers and nonresponders, in cirrhot-
ic patients, African-Americans and those with 
an unfavorable IL28-B profile. It also minimizes 
the relevance of other characteristics, usually un-
favorable ones, associated with the patient (e.g., 
high HOMA), and potentially reduces therapy 
duration. In contrast, this new addition results in 
adverse effects, complex drug-drug interactions 
and potential resistance. Finally, there is greater 
or lesser complexity and high prices. Thus, these 
are decisions to be made in the near future: who 
should be treated with triple therapy and how to 
choose among the available options? 
This is not an easy question to answer. First 
of all, who should be treated? Certainly those in-
fected with genotype 1. It should be clear to all 
that new PIs act only on HCV genotype 1 (with 
evidence of action against genotype 2 and, for 
boceprevir, also against genotype 3).1 The high 
cost should guide selection criteria, including 
economic ones. Prioritizing some patients will be 
a natural choice. In this sense, cirrhotic patients, 
those with advanced fibrosis or at increased risk 
of progression (older patients, those with exuber-
ant inflammatory activity), in addition to those 
previously treated, would be the main candidates. 
The dilemma to be faced is that patients with 
milder disease would be the ones to attain the 
most benefit (with higher rates of SVR), while 
the afore mentioned priority patients besides hav-
ing been less studied have shown lower SVR rates 
(nonetheless overcoming the control group).1-6 
I do not think the answer will come from a sin-
gle source, much less from therapeutic, scientific 
or governmental guidelines. In the context of 
case-by-case and individual decisions, creating 
an inflexible policy is a complex task. Moreover, 
the “price” analysis alone will not suffice. From 
a financial perspective, a complete pharmaco-
economical analysis seems more reasonable. 
Therefore, if a “more expensive” therapy brings 
positive economic impacts in the medium and 
long term, cost-effectiveness will be proven.
Whether we should treat patients with milder 
disease is an unanswered question. These patients 
are in better condition to wait for new therapeutic 
options that will emerge in the coming years. On 
the other hand, on an individual basis, to treat pa-
tients with milder disease is not inadequate and it 
is an option that has sound scientific evidence.1-6 
On the other end of the spectrum, even patients 
with advanced fibrosis should be analyzed indi-
vidually. There has been a grouping of “F3” with 
“F4” (cirrhotic) patients in the analysis of PI piv-
otal studies.2 But do these patients represent the 
same phenomenon? Is the classification method 
(liver biopsy or noninvasive methods) appropri-
ate? Are all cirrhotic patients the same, or would 
cirrhotic patients (by definition) but with good 
functional reserve be better and more responsive? 
The set of factors related to the patient (in-
cluding the socioeconomic ones), to the virus 
and to therapy leading to a case-by-case discus-
sion will be crucial in this decision-making.
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If deciding who will be treated is a complex task, the 
choice between the options available to the clinician and 
the patient – boceprevir or telaprevir – will be another routine 
decision. In this case, four attributes will be decisive: results 
(SVR), compliance, genetic barrier to resistance, and safety. 
A CLOSER LOOK ON TELAPREVIR AND  
BOCEPREVIR
Telaprevir and boceprevir are two different compounds 
(Figure 1) that belong to the same therapeutic class and share 
a common site of action, the HCV protease.7
Although both are classified among the linear protease in-
hibitors, when considering the structural differences of these 
compounds it is natural that their clinical use be distinct in 
terms of administration, dose, drug-drug interactions and ad-
verse events, despite similar clinical efficacy (SVR equivalent). 
Table 1 summarizes some of their attributes.8 
Attribute 1: Attained clinical outcomes (SVR)
The analysis of phase-3 studies of telaprevir and boceprevir 
showed a clear superiority of triple therapy (PegIFN + rib-
avirin + PI) compared to dual therapy (PegIFN + ribavi-
rin).1-6 It is important to emphasize that these are distinct 
studies, with different populations and therefore their re-
sults are not comparable, as there were not head-to-head 
comparisons of the two agents.
One of the characteristics that emphasizes how dif-
ferent the studied populations were, was the observation 
that in the control groups the responses were different 
between the boceprevir and telaprevir studies.1-6 It was 
also noteworthy that the administration of boceprevir 
was preceded by four weeks of dual therapy with PegIFN 
and ribavirin (the lead-in phase), while this strategy was 
used in only one of the telaprevir studies.1,2,4,6 Allowing 
for those caveats, we could emphasize that pooled analy-
sis of overall results showed a difference of 25-28% higher 
(63-66% vs. 38%) in terms of SVR for treatment-naïve 
patients who used triple therapy with boceprevir,1,4 and 
25-31% (69-75% vs. 44%) for those who used telaprevir 
(group 12 weeks) compared to standard.1,3.5
Regarding those previously treated, a 45% higher 
response was obtained in the triple therapy group using 
boceprevir (66% vs. 21%)1,2 and 47% (64% vs. 17%) in 
those who used telaprevir without lead-in, when compared 
to controls with dual therapy.1,6 Among the treatment-na-
ïve patients, 44% to 58% were eligible for shorter therapy 
with boceprevir and telaprevir, respectively.1 In previously 
treated individuals, 46% of those who had used boceprevir 
received abbreviated therapy.1 This information was not 
available for telaprevir, as the criteria for defining the null 
response was distinct for boceprevir (patients who, in the 
lead-in phase, showed less than 1 log10 reduction of the viral 
load).1,2,6 Regarding the lead-in phase, it is used with bo-
ceprevir based on the results of phase-3 studies. In phase-2 
boceprevir studies, a direct comparison between using 
and not using the lead-in showed no significant difference 
Table 1. Similarities and differences between first-generation protease inhibitors*
 Structure Genotype Potency Toxicity Administration Genetic  Sites of 
      barrier resistance
Telaprevir Linear 1a/b High Rash, anemia Tid Low V36M/A
       T54A/S
       V55A
       R155K/T
Boceprevir Linear 1a/b High Dysgeusia, anemia Tid Low A156S/V/T
       V170A
*Adapted from Fusco DN, Chung RT.8
Tid, three times a day.





in terms of SVR (56% vs. 54% in the 28-week groups, and 
75% vs. 67% in the 48-week groups).1 There was a trend to-
ward lower breakthrough among patients who used lead-in 
(4% vs. 9%). As in the Realize study, the arm that performed 
the lead-in with telaprevir showed slight superiority in terms 
of SVR, particularly among relapsers (88% vs. 83%) and null 
responders (33% vs. 29%).1,6 
It seems that the question of performing the lead-in will 
be particularly useful in previously treated patients. This 
initial phase will be important to assess the response to inter-
feron-alpha, to allow pharmacological stability and full effect 
of ribavirin and to better characterize the type of response of 
patients whose previous records, for several reasons, pre-
vented a proper classification. In treatment-naïve patients, it 
may also be useful as a way to measure compliance, evalu-
ate toxicity associated with dual therapy, and even to decide 
not to include the PIs in the regimen of patients with rapid 
virological response (RVR) [around 15% of patients],9 whose 
chance of SVR would be just over 90% in these circumstances. 
Therefore, more than a part of boceprevir-associated therapy, 
the lead-in seems to be an extremely useful tool to catego-
rize patients. On the other hand, not using it is also acceptable 
for both PIs and clinical practice will certainly allow a better 
evaluation of future research on the subject.
Attribute 2: Compliance (administration)
A major difficulty with this first generation of PIs is the pill 
burden. In case of telaprevir, dosage will be 2 tablets every 8 
hours, whereas boceprevir requires intake of 4 pills every 
8 hours. Both require 3 daily doses of pills and a number 
varying between 6 and 12 pills a day.1,10,11 The telaprevir 
therapy lasts for 12 weeks, while boceprevir therapy dura-
tion will vary from 24 to 32 weeks, unless early withdrawal 
interrupts therapy.2,4,11 Consider that it might be necessary 
to associate the use of pegylated interferon to both drugs, 
ribavirin and other drugs to control any adverse symptoms 
and/or concomitant diseases. 
The total treatment time may be 24, 28, 36 or 48 weeks, 
considering the lead-in and the possibility of RGT in 
treatment-naïve patients (24-28 weeks for telaprevir and 
boceprevir, respectively) or previously treated individuals 
(36 weeks, boceprevir) or full therapy (48 weeks for both).1-6 
The number of pills, dose interval and therapy duration 
are therefore critical. But it is also necessary to consider 
the matter of toxicity and drug-drug interactions, which 
will be discussed later, and dietary restrictions. Boceprevir 
should be taken with a light meal.10 
Telaprevir should be taken 30 minutes after a caloric 
(520 calories) and high-fat meal (21 g), or there will be sig-
nificant loss of absorption (up to 237% lower if administered 
in the fasting state).11 Therefore, patients with comorbidities 
such as diabetes, dyslipidemia, cerebrovascular or coronary 
disease will be even more complex to manage. That is, in 
my opinion, the first critical aspect to be discussed with the 
patient is: how many tablets is he/she willing to swallow a 
day and for how long (more or less?). The second aspect will 
be discussed in the Safety item.
Attribute 3: Genetic barrier 
The first-generation PIs share the same problem – a low ge-
netic barrier. Monotherapy rapidly induces the selection of 
resistant variants.
Therefore they must be necessarily used in conjunc-
tion with pegylated interferon and ribavirin (one must be 
careful to avoid the use of an unintended monotherapy, 
for instance, in patients with poor compliance to inter-
feron and ribavirin or in those who have to interrupt dual 
therapy). Furthermore, the subtype 1a has a lower genetic 
barrier than subtype 1b, which requires two amino acid 
substitutions in the codons of viral protease, compared to 
only one for subtype 1a. In order to prevent expanding the 
selection of resistant variants and increasing viral fitness, 
one must be strict when following the rules established 
for each PI interruption.1 In the case of treatment-naïve 
patients using boceprevir, detection of ≥ 100 IU/mL at 
weeks 12 or 24, or ≥ 1000 IU/mL at week 4 or 12, or de-
tected at week 24 when using telaprevir should result in 
therapy withdrawal. With boceprevir for patients previ-
ously treated, detection of > 100 IU/mL at week 12, and 
in the case of telaprevir, > 1000 IU/mL at week 4 or 12, 
should result in therapy withdrawal.1 For both, as previ-
ously discussed, therapy interruption should also occur 
if pegylated interferon or ribavirin have to be removed 
from the regimen. The pattern of mutation that confers 
resistance to both IPs is similar (Table 1). Therefore, 
there is cross-resistance and the rescue of one agent 
by the other is not recommended. New data regarding the 
persistence, variability and the behavior of these resistant 
variables have been reported and it is likely that new rec-
ommendations related to the management of resistance 
will be made soon. 
Attribute 4: Safety
It is known that clinical trials are carried out with highly 
selected populations and do not necessarily represent “real 
life” patients. The interpretation of this strategy may be to 
protect the drug compound being developed from a worst-
case scenario, or simply to minimize interference factors 
that might overshadow the real purpose of the trial, and 
demonstrate the effectiveness of product A or B. Consider-
ing these facts, what is observed in registry studies is the 
efficacy of the drug. Its effectiveness will be the result of 
the attributes that were analyzed (efficacy, compliance, ge-
netic barrier and safety) applied to real-life patients. Thus, 
one shall not be surprised to find results that are not iden-
tical to those described in registry studies. In the specific 
case of PIs, the question of compliance will be relevant, 
but the capacity to maintain patients on therapy will be 
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decisive! In general, in phase-3 studies, adverse events 
leading to therapy discontinuation occurred in 12-16% 
of patients with boceprevir (versus 16% in controls) and 
16.5% in those using telaprevir (versus 4.1% in controls).1-6 
Therefore, safety will be the main factor to keep patient on 
therapy. The item safety should be divided into two topics: 
drug-drug interactions and adverse effects.
Telaprevir is a substrate and an inhibitor of cytochrome 
P3A (CYP3A) and P-glycoprotein (P-gp).1,12 It inhibits both 
CYP3A and P-gp. The use of drugs that depend on the me-
tabolization by this CYP3A pathway is contraindicated due 
to the potential increase of its plasma concentration, lead-
ing to significant toxicity. One example of this mechanism 
is simvastatin.1,12,13 Immunosuppressive agents such as cy-
closporine and tacrolimus administered concurrently with 
telaprevir also showed extremely high levels, to the point 
of severe toxicity risk.14 Other interactions may occur with 
compounds that interact with these metabolic and transpor-
tation pathways. Boceprevir is a substrate of P-gp, which is 
partially metabolized by CYP3A, also inhibited by it.1,13,15 
Therefore, it also undergoes the complex interactions with 
drugs that depend on the CYP3A pathway, such as simvas-
tatin. Another drug that is contraindicated with both PIs is 
rifampicin, for it induces CYP3A and reduces the concentra-
tions of both PIs.12,13,15 Furthermore, benzodiazepines such 
as midazolam are formally contraindicated for concomitant 
use with PIs.1,2,13,15 The use of concomitant medications has 
been the subject of specific retrospective analysis of phase-3 
studies soon to be presented, with new information on safe-
ty. However, it is advisable that prescription of PIs be made 
after consulting specific sites with updates on the safe use 
of drugs together with the PIs. One recommended source is 
www.hep-druginteractions.org. The complexity of potential 
interactions is a relevant factor when making the decision 
to delay therapy. Both in elderly patients and those who will 
grow old until they are treated, the potential of diagnosis of 
new comorbidities that require specific therapy must be bal-
anced against initiating therapy against HCV in a stage of 
life where such risk of interaction is absent. 
As for safety itself, it is undeniable that we are currently 
living a time of transition. We left the highly controlled clini-
cal trials for the therapeutic use of these new drug compounds 
in real life. Out here, there is no selection, there is no easy care. 
This is about the physician, the patient and the social envi-
ronment, including available assistance resources. Clearly, we 
have entered a new era. New adverse effects emerged from 
the management of hepatitis C therapy. In addition to the 
known hematologic toxicity, especially anemia, we have been 
introduced to dermatological and systemic events with lethal 
potential, and less severe, but equally important events, such 
as anorectal symptoms and dysgeusia. It is also true that diag-
nostic and therapy management rules have been determined 
to handle skin events and the publication of scientific articles 
addressing adverse skin events is growing.16,17 Finally, the 
dermatologist will be a new member of the multidisciplinary 
team and the use of erythropoietin should be more frequent. 
In phase-3 studies, anemia was observed with both PIs. 
Hemoglobin < 10 g/dL occurred in 49% of patients receiv-
ing boceprevir (29% in controls) and 9% had hemoglobin 
< 8.5 g/dL. Erythropoietin was used in 45% of patients (24% 
in controls). However, discontinuation due to anemia was 
low, 2%, as compared to 1% among the controls. Likewise, 
therapy withdrawal due to serious adverse events was com-
parable between control and boceprevir (11% vs. 8%).1,2,4 
Patients who used telaprevir with hemoglobin < 10 g/dL 
were 36% (14% in controls) and 9% had hemoglobin 
< 8.5 g/dL. The use of erythropoietin was prohibited in tel-
aprevir studies. Thus, 5-6% of patients with anemia using 
telaprevir had to interrupt the therapy.1,3,5,6
In France, according to data presented by Hézode18 at 
the National French Liver Meeting in 2011, of 109 patients 
taking boceprevir, 21% had hemoglobin levels between 8 
and 10 g/dL and 6% < 8 g/dL. Erythropoietin was used in 
41% of them and blood transfusion in 4%. In relation to tel-
aprevir, of 107 patients, 24% had hemoglobin levels between 
10 g/dL and 8 g/dL and 13% < 8 g/dL. Erythropoietin was 
used in 45% of the cases and 17% required blood transfu-
sions. This is a very different scenario from that in clinical 
studies. Anemia seems to be a common event with telaprevir 
and boceprevir therapy, with similar management and magni-
tude, but with different severity, which may eventually reflect 
some particular clinical feature of the assessed population.
We must also consider the fact that severe anemia 
(Hb < 8.5 g/dL) occurred in less than 10% of patients. Most 
patients with anemia are in the range of usual therapeutic 
management for the clinicians who already dealt with in-
terferon alpha-based therapy. In addition, ribavirin dose 
reduction is an effective, alternative measure to erythropoi-
etin use and does not interfere with therapy effectiveness.
Dysgeusia was reported in 35% of patients who re-
ceived boceprevir (16% in controls) and 10% of patients 
who received telaprevir (3% in controls). Anorectal 
events were reported only in patients who received tel-
aprevir (26.2% vs. 5% in controls). Initially these events 
were reported as “hemorrhoids” and later referred to as anal 
itching, anorectal discomfort and hemorrhoids. The onset 
occurs in the first two weeks of therapy and its mechanism 
is unknown. Proctologic examination is usually normal and 
not associated with skin alterations or the presence of pruri-
tus. There is no standard therapy and progressive improve-
ment occurs after telaprevir withdrawal.1-6
Finally, let’s address dermatologic events of phase-3 
studies.1-6 Skin rash was observed in 17% of patients us-
ing boceprevir. However, when compared to controls, in 
this group, the presence of rash was 19%. Therefore, it is 
not reasonable to believe that this effect is explained only 
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by the boceprevir, as we know that ribavirin is also associ-
ated with adverse skin events. On the other hand, 56% of 
patients using telaprevir had rash compared with 32% 
of controls. In most cases it was mild to moderate, but 4% of 
them had more than 50% of body surface affected and in 7% 
of cases, it led to therapy withdrawal. Pruritus occurred in 
50% of patients taking telaprevir whereas Stevens-Johnson 
syndrome or drug-related eruption with systemic symptoms 
(DRESS) was reported in approximately 1% of patients us-
ing telaprevir. That is a severe, potentially lethal manifesta-
tion and one that requires permanent telaprevir withdrawal. 
In this case, only as speculation, it is possible to consider 
the use of boceprevir as PI rescue in order to maintain the 
potential to treat hepatitis C when the condition is under 
control. The data reported so far are quite relevant. Hézode18 
identified 7% of severe rash among the 107 patients followed 
in France. Therefore, we must be alert and prepared to diag-
nose and manage these events, highlighting what the use of 
these drugs could represent in a country with tropical char-
acteristics (hot, humid and sunny) such as Brazil. 
Concerning future discussions with our patients, we 
must yet again openly discuss what risks he or she is willing 
to take – more or less? The options to be offered are a long-
er treatment with more pills, but with fewer adverse events 
(anemia, dysgeusia) – more is less – or a shorter and simpler 
treatment, but with a higher risk of adverse and severe events 
(anemia, dysgeusia, anal discomfort, allergic and dermato-
logic events) – less is more. The risk associated with PIs is 
greater than that with dual therapy. This must be made clear 
to the doctor and patient. Thus, the balance between compli-
ance and safety will not be decided only by the physician, but 
also by the adequately informed patients and their families. 
CONCLUSIONS
We have finally got what we were demanding: better hepa-
titis C therapy! We, forever dissatisfied individuals, must 
recognize that therapy is still far from what is desired. It is 
not 100% effective, it is less effective in cirrhotics and non-
responders, it is not pan-genotypic, it can select resistant 
variants, it is complex and, above all, it brings new and po-
tentially lethal adverse events and interactions.
On the other hand, it is superior, regarding all aspects 
and comparisons, to dual therapy with pegylated inter-
feron and ribavirin. It also allows reducing therapy time 
from the current 48 to 72 weeks to 24 to 28 weeks in most 
patients, and up to 36 weeks in previously treated ones.
This therapy also has a better cost-effectiveness and may 
be used, as we soon shall see, in patients coinfected with HIV. 
The American Association for the Study of Liver Diseases 
(AASLD) has recommended triple therapy as the standard 
therapy to those infected by genotype 1.1 Thus, before we fear 
it, we must get ready for it. And above all, we must decide: 
whom to treat, how to treat? It is my opinion that candidates 
for therapy will increase in numbers. If we consider these 
drugs to be cost-effective, all those infected with genotype 1 
that require therapy should be treated. If we are more con-
servative, all those previously treated without success should 
be treated. If we are even more conservative, those with ad-
vanced fibrosis, above F3, should be treated. The only thing 
we cannot afford to do is not to decide. The prospect that new 
drug compounds and new DAA classes are to be made avail-
able is real. The problem is that it will not ensue immediately. 
Conservatively, perhaps we will have new therapeutic agents 
available in the next three to five years. This is a time period 
that many patients, unfortunately, cannot afford to wait. 
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